Clinical Trials Directory

Trials / Conditions / Severe Acute Respiratory Syndrome Coronavirus 2

Severe Acute Respiratory Syndrome Coronavirus 2

45 registered clinical trials studyying Severe Acute Respiratory Syndrome Coronavirus 2.

StatusTrialSponsorPhase
UnknownA Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine
NCT05947812
60P Australia Pty LtdPhase 2
Active Not RecruitingA Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
NCT05543616
BioNTech SEPhase 3
CompletedA Clinical Trial of COVAC-2 in Adults
NCT05209009
University of SaskatchewanPhase 2
UnknownNA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Biomed Industries, Inc.Phase 2 / Phase 3
WithdrawnA Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults
NCT05155982
University of SaskatchewanPhase 1
WithdrawnCOVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
NCT04381923
University of PennsylvaniaN/A
UnknownEarly Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection
NCT04920838
ANRS, Emerging Infectious DiseasesPhase 2 / Phase 3
TerminatedAntiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
NCT04409873
University of California, San FranciscoPhase 2
CompletedCommunication in ICU During COVID-19
NCT04602351
NMC Specialty Hospital
TerminatedIsavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
NCT04707703
Jeffrey Jenks, MD, MPHPhase 3
CompletedA Clinical Trial of COVAC-2 in Healthy Adults
NCT04702178
University of SaskatchewanPhase 1
WithdrawnMetformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
NCT04626089
Laboratorios Silanes S.A. de C.V.Phase 2
SuspendedFluvoxamine for Adults With Mild to Moderate COVID-19
NCT04711863
Asan Medical CenterPhase 2
CompletedStudy to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
NCT04732949
Synairgen Research Ltd.Phase 3
CompletedCombination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase
NCT04466241
ANRS, Emerging Infectious DiseasesPhase 2 / Phase 3
UnknownCORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
NCT04402879
University of CalgaryN/A
TerminatedEfficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
NCT04371978
Rabin Medical CenterPhase 3
UnknownTherapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
NCT04516811
South African National Blood ServicePhase 3
CompletedTreatment of SARS Caused by COVID-19 With Ruxolitinib
NCT04334044
Grupo Cooperativo de Hemopatías MalignasPhase 1 / Phase 2
UnknownDaily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia
NCT04519125
Hospital Universitario San IgnacioPhase 2 / Phase 3
CompletedAn Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
NCT04522986
Rohto Pharmaceutical Co., Ltd.Phase 1
TerminatedRuxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
NCT04477993
Vanderson Geraldo RochaPhase 2 / Phase 3
UnknownTocilizumab in Coronavirus-19 Positive Patients
NCT04423042
University of CalgaryPhase 3
CompletedMetformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SA
NCT04625985
Laboratorios Silanes S.A. de C.V.Phase 2
CompletedVagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
NCT04379037
Nemechek TechnologiesN/A
CompletedA Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroq
NCT04461353
Pulmoquine Therapeutics, IncPhase 1
CompletedCOVID-19 Related Health and Infection Control Practices Among Dentists
NCT04423770
American Dental Association
CompletedA Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
NCT04402060
Apellis Pharmaceuticals, Inc.Phase 1 / Phase 2
UnknownNatural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
NCT04365101
Celularity IncorporatedPhase 1 / Phase 2
CompletedAntibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
NCT04354779
AUVA
UnknownSurgery and Lung Ultrasound in COVID-19 Infection
NCT04661631
Fundacion Clinica Valle del Lili
CompletedHost-pathogen Interactions During SARS-CoV-2 Infection
NCT04376476
Hospices Civils de LyonN/A
CompletedEfficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
NCT04375098
Pontificia Universidad Catolica de ChilePhase 2
UnknownAfrican Covid-19 Critical Care Outcomes Study
NCT04367207
University of Cape Town
CompletedScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Ca
NCT04367740
University of North Carolina, Chapel Hill
UnknownMonocytes and NK Cells Activity in Covid-19 Patients
NCT04375176
Università degli Studi dell'Insubria
CompletedProne Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients
NCT04359407
Walid HABRE
UnknownRuxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
NCT04361903
Azienda USL Toscana Nord Ovest
CompletedRisk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections
NCT04357938
Jena University Hospital
CompletedBeaumont Health Large-scale Automated Serologic Testing for COVID-19
NCT04349202
Corewell Health East
CompletedPro-thrombotic Status in Patients with SARS-Cov-2 Infection
NCT04343053
University Hospital of FerraraN/A
CompletedCell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
NCT04333368
Assistance Publique - Hôpitaux de ParisPhase 1 / Phase 2
Active Not RecruitingPulmonary Fibrosis During Severe COVID-19 Pneumonia
NCT04987528
Hôpital Européen Marseille
CompletedEvaluation of Sedation in COVID-19 ARDS
NCT04667936
Goethe University
No Longer AvailableTreatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486
U.S. Army Medical Research and Development Command